Louise Rodino-Klapac - Mar 6, 2025 Form 4 Insider Report for Sarepta Therapeutics, Inc. (SRPT)

Role
Head of R&D, CSO
Signature
/s/ Cristin Rothfuss, as Attorney-in-Fact for Louise Rodino-Klapac
Stock symbol
SRPT
Transactions as of
Mar 6, 2025
Transactions value $
-$881,865
Form type
4
Date filed
3/10/2025, 08:00 PM
Previous filing
Mar 6, 2025
Next filing
Mar 11, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SRPT Common Stock Options Exercise +17.5K +26.79% 82.8K Mar 6, 2025 Direct F1
transaction SRPT Common Stock Tax liability -$53.3K -514 -0.62% $103.70 82.3K Mar 7, 2025 Direct F2
transaction SRPT Common Stock Tax liability -$829K -7.99K -9.71% $103.70 74.3K Mar 7, 2025 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SRPT Performance Stock Units Options Exercise $0 -17.5K -100% $0.00 0 Mar 6, 2025 Common Stock 17.5K Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the number of shares vested under a performance stock unit ("PSU") award granted to the Reporting Person on March 6, 2023. The number of shares earned was based on the Compensation Committee's determination of the Company's achievement of the milestones under the terms of the PSU.
F2 Shares were sold by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 6, 2023.
F3 Shares were sold by the Company to satisfy tax withholding obligations related to vesting of PSUs granted on March 6, 2023.